GW PHARMACEUTICALS PLC
GWPH evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- epidiolex (Phase 3)
What it means
What to watch
Prepared research question
What matters most for GWPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates for GW PHARMACEUTICALS PLC.
Similar companies
Run GW PHARMACEUTICALS PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GW PHARMACEUTICALS PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is GW PHARMACEUTICALS PLC's lead drug candidate?
GW PHARMACEUTICALS PLC's most advanced tracked candidate is epidiolex (Phase 3) for Rett syndrome.
Who is the CEO of GW PHARMACEUTICALS PLC?
San Francisco is the chief executive officer of GW PHARMACEUTICALS PLC (GWPH).
What therapeutic areas does GW PHARMACEUTICALS PLC focus on?
GW PHARMACEUTICALS PLC develops therapies across Rare Disease, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.